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Background: Niemann-Pick disease Type C (NP-C) is difficult to diagnose due to heterogeneous and nonspecific
clinical presentation. The NP-C Suspicion Index (SI) was developed to identify patients with a high likelihood of NP-C;
however, it was less reliable in patients aged <4 years.
Methods: An early-onset NP-C SI was constructed following retrospective chart review of symptom presentation in
200 patients from nine centres comprised of 106 NP-C cases, 31 non-cases and 63 controls. Statistical analyses defined
strength of association between symptoms and a diagnosis of NP-C and assigned risk prediction scores to each
symptom.
Results: Visceral symptoms were amongst the strongest predictors. Except for gelastic cataplexy and vertical
supranuclear gaze palsy, central nervous system symptoms were not discriminatory in this population. Performance of
the early-onset NP-C SI was superior versus the original NP-C SI in patients aged ≤4 years.
Conclusions: The early-onset NP-C SI can help physicians, especially those with limited knowledge of NP-C, to identify
patients aged ≤4 years who warrant further investigation for NP-C.
Keywords: Niemann-Pick disease Type C, NP-C, Suspicion Index, Paediatric, Infant, Early-onset, Diagnosis, Diagnostics,
ScreeningBackground
Niemann-Pick disease Type C (NP-C) [OMIM #257220,
NP-C1; #607625, NP-C2] is a severe, autosomal recessive
lysosomal lipid storage disorder caused by mutations in
NPC1 or NPC2 genes [1]. NP-C has multiple presentations,
with a wide range of visceral, neurological and psychiatric
symptoms [2, 3].
NP-C can present at any age [1, 4]. Patients who develop
symptoms during the early infancy (2 months to 2 years of
age) have mainly visceral manifestations, including spleno-
megaly, hepatomegaly, prolonged unexplained neonatal
jaundice, and direct hyperbilirubinaemia, which precede* Correspondence: pineda@hsjdbcn.org
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manifestation and the progression of neurological features
usually define disease severity [1]. Neurological and psy-
chiatric presentation varies with age at onset. In infancy,
symptoms include delay of motor milestones, language
delay, regression of previously achieved developmental
level, central hypotonia, ataxia and gelastic cataplexy.
Juvenile-onset patients commonly present with problems
at school, intellectual decline, vertical supranuclear gaze
palsy (VSGP), dysmetria, cerebellar ataxia, progressive
dysarthria or dysphagia, and in some cases, seizures. Psy-
chiatric disorders and progressive dementia are common
in adolescence and adulthood [1, 5, 6].
The heterogeneous and often nonspecific clinical pres-
entation of NP-C means that diagnosis can be delayed
for many years [1, 7, 8]. Typically, a diagnosis is
confirmed by biochemical (filipin staining of skinle is distributed under the terms of the Creative Commons Attribution 4.0
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NPC1 and NPC2 genes, the loci that confer 95 % and
5 % of NP-C cases, respectively) [7, 9]; however, rapid
biochemical tests utilising biomarkers such as plasma
oxysterols or lysosphingolipids are in development, and
may improve rates of diagnosis [10–12].
Miglustat (Zavesca®, Actelion Pharmaceuticals Ltd,
Allschwil, Switzerland) can slow the progression of irre-
versible neurological manifestations, and is the only ap-
proved treatment for the disease [5, 13, 14]. Patients
who begin miglustat therapy at the onset of neurological
symptoms may maintain higher levels of neurological
function, highlighting the importance of early diagnosis
and treatment initiation.
An NP-C Suspicion Index (SI) tool was developed
based on a retrospective chart review of NP-C signs and
symptoms, to assist clinicians who may be unfamiliar
with NP-C in identifying patients who should undergo
testing for the disease [15]. Analysis of the NP-C SI dis-
criminatory power by patient age showed high perform-
ance in patients aged ≥4 years, but poor performance in
patients with early-onset NP-C (aged <4 years) [6]. In
the current study, additional data on patients ≤4 years of
age were collected to provide a new database, and de-
velop a novel NP-C SI with improved utility in this pa-
tient population. This new NP-C SI will be useful to
support physicians with no knowledge of NP-C to more
easily identify patients with the disease.
Methods
Determining signs and symptoms of patients with early-
onset NP-C
Based on a complete list of signs and symptoms for
diagnosis of NP-C in patients aged ≤4 years, we devel-
oped a corresponding Medical Chart Record Form
(MCRF; Additional file 1: Figure S1). These signs and
symptoms were subdivided into the four clinical pres-
entation categories used in the development of the
original NP-C SI: central nervous system (CNS, com-
prising neurological and behavioural signs), visceral
signs, family history and psychiatric symptoms [15]
(Additional file 2: Table S1), to allow direct comparison
between the original and new early-onset NP-C SI.
Study centres and patient inclusion criteria
The retrospective chart review of patients was con-
ducted in nine specialist centres in Brazil (Clinics Hos-
pital of Ribeirão Preto, University of São Paulo and
Barão de Lucena Hospital, Recife PE), Czech Republic
(Charles University and General University Hospital,
Prague), France (CHU Trousseau, Paris and MaMEA,
Necker-Enfants Malades and IMAGINE Institute,
APHP, Paris), Germany (MC University of Mainz), Iran
(Mofid Children Hospital, Tehran), Spain (FundacióHospital Sant Joan de Deu, Barcelona), and the UK
(Saint Mary’s Hospital, Manchester and University of
Manchester). Participating centres consecutively se-
lected all patients who fulfilled the inclusion criteria
and did not fulfil the exclusion criteria. For inclusion,
patients aged ≤4 years were classified into one of the
following subgroups:
1. NP-C case: classical or variant filipin staining and/or
2 known mutations in NPC1 or NPC2;
2. NP-C non-case: confirmed NP-C negative by filipin
staining or maximum of 1 mutation in NPC1 or
NPC2;
3. Controls: one characteristic clinical symptom of
NP-C, but not suspected of having the disease,
selected from the same specialist centres as the
NP-C cases and NP-C non-cases.
Patients were excluded if they were known to have a
metabolic disease other than NP-C.
Standard protocol approvals, registrations and patient
consents
All patient data were blinded by the experts so that
names, addresses or other identifying information were
not available to any other party involved in the analysis
or review of the data. Therefore, the study did not re-
quire approval by an ethical standards committee. All in-
vestigators adhered to local privacy laws and regulations
to ensure patient confidentiality.
Data collection
Data were collected retrospectively, between November
2012 and February 2014, into the MCRF which struc-
tured the dataset for use in tool development.
Hepatomegaly and splenomegaly were represented
as individual items in the analysis. The collection term
direct bilirubinaemia was used to reflect a finding of
direct hyperbilirubinaemia. The term cognitive decline
was used for data collection, but was not considered
appropriate for use in this patient population, with
mental regression being preferred by the authors. The
term mental regression was therefore used during tool
development. It was also acknowledged that mental
regression should be considered as a CNS sign rather
than a psychiatric sign, and was therefore included
alongside other CNS signs in the subsequent analyses
(Additional file 1: Figure S1 and Additional file 2:
Table S1).
Statistical analysis
Data were summarised descriptively for NP-C cases, NP-C
non-cases and controls. For data analysis, the variables were
the individual signs and symptoms outlined in Additional
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likelihood of NP-C was modelled via univariate logistic re-
gression using NP-C cases as a reference group in two
models: 1. versus NP-C non cases; 2. versus controls. No
variable selection procedure was used in the modelling as
all collected variables were considered to be important
when screening patients aged ≤4 years for NP-C. All statis-
tical analyses were conducted with Statistical Analysis Sys-
tem (SAS) v9.3.
NP-C risk prediction score and early-onset NP-C SI
construction
Prediction scores were based on regression coefficients
obtained from the univariate logistic regression models of
each sign and symptom of NP-C, each item of family his-
tory, and combinations of signs and symptoms. The result-
ing regression coefficients were multiplied by 10 and
rounded to integer values. A weighted mean of these values
was calculated by applying 0.25 weight to values derived
from the analysis of NP-C cases versus NP-C non-cases,
and 0.75 weight to values derived from analysis of NP-C
cases versus controls. Based on the distribution of the
resulting values, a simplified scoring system was devised,
assigning each value to one of the following categories with
an associated risk prediction score (RPS): ancillary = 1;
weak = 2; moderate = 3; strong = 4; very strong = 6. All po-
tential combinations of two symptoms were assessed for
predictive power. The combinations that added to the dis-
criminatory performance of the early-onset NP-C SI model
were included as modifier symptoms.
The final early-onset NP-C SI was developed itera-
tively, using different combinations of the signs and
symptoms shown to have positive predictive power, to
provide optimal discriminatory performance between
NP-C cases, NP-C non-cases and controls. Several
models were evaluated to assess robustness and sensitiv-
ity. The inclusion of any specific sign or symptom in the
final tool was determined by its ability to discriminate
NP-C cases from NP-C non-cases and NP-C cases from
controls. Only signs and symptoms specific to NP-C
were included in the final NP-C SI.
Validation of the early-onset NP-C SI
The final scoring system was applied to individual pa-
tient data to calculate their total RPS and to perform
univariate logistic regression. The performance of the
total RPS and the individual prediction scores of each
subgroup were investigated via receiver operating char-
acteristic (ROC) curve and area under the curve (AUC)
analysis. Sensitivity and specificity values versus the total
RPS were plotted at defined intervals to facilitate selec-
tion of cut-off points for grading suspicion as low, mod-
erate and high. Validation of the total RPS was
performed using bootstrap resampling [16] to obtain abootstrap-corrected estimate of the AUC for NP-C cases
versus NP-C non-cases and NP-C cases versus controls.
The new patient cohort was applied to both the early-
onset NP-C SI model and the original NP-C SI and com-
parative predictive performance assessed via ROC AUC
analysis.
Results
Patient characteristics
In total, 200 patients were included (106 NP-C cases; 31
NP-C non-cases; 63 controls) from nine expert centres in
seven countries. Median age at diagnosis for NP-C cases
was lower versus NP-C non-cases (16.5 and 33.0 months,
respectively) and similar to controls (23.0 months). Three
patients aged greater than 48 months were included in the
analysis to improve the accuracy of data collected at the
upper boundary of the age range (Table 1).
Key symptomatology
The key clinical symptoms of NP-C in this patient cohort,
defined as those observed in ≥5 % of NP-C cases, are de-
tailed in Table 1, and the data for all symptoms are shown
in Additional file 3: Table S2. Visceral symptoms were
highly suggestive of NP-C, including splenomegaly (78 %
of NP-C cases versus 58 % of NP-C non-cases and 37 % of
controls), hepatomegaly (70 % of NP-C cases versus 58 %
of NP-C non-cases and 49 % of controls), and prolonged
jaundice (56 % of NP-C cases versus 45 % of NP-C non-
cases and 24 % of controls). Direct bilirubinaemia was
similar in NP-C cases and NP-C non cases (42 % in each),
but was less common in controls (17 %).
Overall, CNS symptoms were reported at a lower
frequency than visceral signs, but many distinguished
NP-C cases from NP-C non-cases and controls, includ-
ing gelastic cataplexy, VSGP and mental regression. In
contrast, the occurrence of ataxia differentiated poorly
between NP-C cases (32 %), NP-C non-cases (29 %), and
controls (33 %). Developmental delay, with symptoms
defined individually as deficits in language acquisition,
gross motor function, or fine motor function, were com-
mon presenting features in NP-C cases (39 %, 40 % and
30 %, respectively), but were also common in NP-C
non-cases and controls.
There were signs and symptoms that occurred at low
frequency that were specific to NP-C cases. The most
specific of these, parents or siblings with NP-C, was
present in 24 % of NP-C cases and absent in NP-C non-
cases and controls. Pulmonary infiltrates occurred in
only 13 % of NP-C cases, but were less frequent in NP-C
non-cases and controls (3 % and 2 %, respectively).
Construction of the early-onset NP-C SI
Univariate logistic regression modelling produced an
abbreviated list of nine signs and symptoms that were
Table 1 Summary of patient demographics and NP-C symptomatology observed in ≥5 % of NP-C cases
NP-C cases (n = 106) NP-C non-cases (n = 31) Controls (n = 63) All patients (N = 200)
Recruitment sites, n (%)
Brazil 16 (15) 3 (10) 13 (21) 32 (16)
Czech Republic 6 (6) 0 (0) 6 (10) 12 (6)
France 14 (13) 2 (6) 17 (27) 33 (17)
Germany 19 (18) 14 (45) 0 (0) 33 (17)
Iran 8 (8) 2 (6) 1 (2) 11 (6)
Spain 12 (11) 10 (32) 15 (24) 37 (19)
United Kingdom 31 (29) 0 (0) 11 (17) 42 (21)
Gender, n (%)
Male 54 (51) 22 (71) 27 (43) 103 (52)
Female 52(49) 9 (29) 36 (57) 97 (49)
Age (months)
Mean (±SD) 20.8 (16.7) 29.0 (16.8) 21.9 (14.2) 22.4 (16.2)
Median 16.5 33.0 23.0 21.5
Minimum, maximum 0.0, 58.0 2.0, 48.0 1.0, 48.0 0.0, 58.0
Central nervous system, n (%)
Neurological symptoms
Acquired and progressive spasticity
Yes 17 (16) 4 (13) 21 (33) 42 (21)
No/no data 89 (84) 27 (87) 42 (67) 158 (79)
Ataxia
Yes 34 (32) 9 (29) 21 (33) 64 (32)
No/no data 72 (68) 22 (71) 42 (67) 136 (68)
Delayed development
Language acquisition
Yes 41 (39) 14 (45) 32 (51) 87 (44)
No/no data 65 (61) 17 (55) 31 (49) 113 (57)
Gross motor function
Yes 42 (40) 18 (58) 42 (67) 102 (51)
No/no data 64 (60) 13 (42) 21 (33) 98 (49)
Fine motor function
Yes 32 (30) 14 (45) 34 (54) 80 (40)
No/no data 74 (70) 17 (55) 29 (46) 120 (60)
Deterioration or loss of previously acquired physical skills
Yes 31 (29) 6 (19) 27 (43) 64 (32)
No/no data 75 (71) 25 (81) 36 (57) 136 (68)
Dysphagia (± dysarthria)
Yes 21 (20) 2 (6) 22 (35) 45 (23)
No/no data 85 (80) 29 (94) 41 (65) 155 (78)
Gelastic cataplexy
Yes 6 (6) 0 (0) 0 (0) 6 (3)
No/no data 100 (94) 31 (100) 63 (100) 194 (97)
Hypotonia
Yes 46 (43) 19 (61) 39 (62) 104 (52)
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No/no data 60 (57) 12 (39) 24 (38) 96 (48)
Mental regression
Yes 13 (12) 1 (3) 8 (13) 22 (11)
No/no data 93 (88) 31 (97) 55 (87) 179 (90)
Urinary and faecal incontinence inappropriate to age
Yes 13 (12) 6 (19) 13 (21) 32 (16)
No/no data 93 (88) 25 (81) 50 (79) 168 (84)
VSGP
Yes 14 (13) 0 (0) 5 (8) 19 (10)
No/no data 92 (87) 31 (100) 58 (92) 181 (91)
Behavioural problems
Deterioration of previously acquired mental skills
Yes 21 (20) 6 (19) 15 (24) 42 (21)
No/no data 85 (80) 25 (81) 48 (76) 158 (79)
Deterioration of social interaction
Yes 9 (8) 3 (10) 19 (30) 31 (16)
No/no data 97 (92) 28 (90) 44 (70) 169 (85)
Visceral symptoms, n (%)
Liver signs
Hepatomegaly (historical or current)
Yes 74 (70) 18 (58) 31 (49) 133 (62)
No 32 (30) 13 (42) 32 (51) 77 (39)
Increased conjugated direct bilirubin levels
Yes 44 (42) 13 (42) 11 (17) 68 (34)
No/no data 62 (58) 18 (58) 52 (83) 132 (66)
Prolonged unexplained neonatal jaundice or cholestasis
Yes 59 (56) 14 (45) 15 (24) 88 (44)
No/no data 47 (44) 17 (55) 48 (76) 112 (56)
Spleen signs
Low platelet count (<150 × 109/L)
Yes 13 (12) 10 (32) 13 (21) 36 (18)
No 93 (88) 21 (68) 50 (79) 164 (82)
Unexplained splenomegaly (historical or current)
Yes 83 (78) 18 (58) 23 (37) 124 (62)
No 23 (22) 13 (42) 40 (63) 76 (38)
Pulmonary signs
Pulmonary infiltrates
Yes 14 (13) 1 (3) 1 (2) 16 (8)
No/no data 92 (87) 30 (97) 62 (98) 184 (92)
Pre- and peri-natal symptoms
Foetal oedema or ascites
Yes 5 (5) 2 (6) 1 (2) 8 (4)
No/no data 101 (95) 29 (94) 62 (98) 192 (96)
Family history, n (%)
Consanguinity of parents
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Yes 22 (21) 5 (16) 15 (24) 42 (21)
No/no data 84 (79) 26 (84) 48 (76) 158 (79)
Parents or siblings with NP-C
Yes 25 (24) 0 (0) 0 (0) 25 (13)
No/no data 84 (79) 31 (100) 63 (100) 175 (89)
N, number of patients in population; n, number of patients with assessment; NP-C Niemann-Pick disease Type C, SD standard deviation, VSGP vertical supranuclear
gaze palsy
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cases or controls. These signs and symptoms were: parents
or siblings with NP-C; pulmonary infiltrates; splenomegaly;
gelastic cataplexy; prolonged jaundice; VSGP; direct biliru-
binaemia; foetal oedema or ascites; hepatomegaly. Indi-
vidually, mental regression and ataxia poorly associated
with NP-C cases, but in combination with other CNS
symptoms or splenomegaly these associations were stron-
ger. These two symptoms were included in the final model
as modifier signs and symptoms.
RPS and validation
Each of the nine signs or symptoms was assigned RPS
points based on the outcome of the regression analysis
(Additional file 4: Table S3). The two modifier symptoms
provided additional points to the RPS, only in the pres-
ence of other, more specific signs and symptoms. The
proposed early-onset NP-C SI, using the assigned RPS
points for each of the signs and symptoms, is presented
in Fig. 1.
The cut-off scores for low, moderate and high risk of
NP-C were assigned based on sensitivity and specificity
analyses of NP-C cases versus NP-C non-cases and NP-C
cases versus controls (Fig. 2). RPS for each category was
set as: <3 points, low suspicion; 3–5 points, moderateFig. 1 The early-onset NP-C SI. Symptoms were scored based on the stren
CNS signs ataxia and mental regression only contribute additional RPS poin
splenomegaly. CNS, central nervous system; RPS, risk prediction score; SI, Sususpicion; ≥6 points, high suspicion. The cut-off score for
low suspicion (3 points) corresponds to a specificity of
58.4 % and sensitivity of 89.6 %. The cut-off score for high
suspicion (6 points) corresponds to specificity of 83.8 %
and sensitivity of 72.8 %. RPS distributions and means
[± standard deviation] clearly demonstrate good discrim-
ination between NP-C cases (9.6 [5.2]), NP-C non-cases
(5.5 [3.8]) and controls (3.3 [3.1]; Additional file 5:
Figure S2).
ROC curve analysis with the new patient cohort using
the early-onset NP-C SI (NP-C cases versus controls,
AUC = 0.885 [CI: 0.799, 0.911]) and the original SI
(NP-C cases versus controls, AUC = 0.603 [CI: 0.517,
0.689]) showed an improvement in predictive power
with the new early-onset NP-C SI (Fig. 3a). Neither CNS
symptoms nor family history alone were sensitive or spe-
cific predictors of NP-C (AUC: CNS symptoms = 0.546;
family history = 0.618). Visceral symptoms alone were a
good predictor of NP-C (AUC = 0.813; Fig. 3b).
Discussion
This retrospective chart review describes a detailed exam-
ination of symptomatology at time of diagnosis in patients
with NP-C aged ≤4 years, and has allowed the develop-
ment of a novel NP-C SI for use in this patient population.gth of association with a diagnosis of NP-C in the present cohort. The
ts in the presence of other CNS signs (gelastic cataplexy, VSGP) or
spicion Index; VSGP, vertical supranuclear gaze palsy
Fig. 2 Performance assessment (sensitivity and specificity) plots for
NP-C cases versus NP-C non-cases and controls. High sensitivity and
specificity was achieved with NP-C cases versus NP-C non-cases or
controls, and aided the assignment of cut-off scores (vertical dashed
lines) for low (<3), moderate (3–5) and high (≥6) likelihood
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NP-C diagnoses does not allow the recruitment of a suffi-
cient number of patients for a prospective study. It is an-
ticipated that the ongoing use of the early-onset NP-C SI
in clinical practice will confirm the strength of the statis-
tical analyses and the validity of the early-onset NP-C SI
as a clinical aid.
In contrast with the patient cohort used to develop the
original NP-C SI, [15] confirming a positive diagnosis in
the early-onset NP-C population did not require both fili-
pin staining and genetic testing. Positive filipin staining
alone was considered sufficient for diagnosis, as uncertain
diagnoses due to variant-staining are very uncommon at
this age, being observed more frequently in patients with
late-onset NP-C [17].
One of the strengths of the present study is that all
patients (NP-C cases, NP-C non-cases and controls)
were recruited from the same clinical settings, broad-
ening the universal utility of the NP-C SI in routine
clinical practice. The principle weakness of the study
is that the resulting NP-C SI is defined by the pheno-
types of this particular patient cohort. As such, if the
observed frequency of any given symptom is not rep-
resentative of the incidence within the global early-
onset NP-C patient population, the discriminatorypower of the NP-C SI could be biased in favour of,
or against that symptom when applied in routine clin-
ical practice.
The present study includes a detailed clinical descrip-
tion of the largest cohort of patients aged ≤4 years with
NP-C studied to date (Table 1 and Additional file 3:
Table S2). This description is in broad agreement with
the typical presentation of NP-C in patients within this
age group. Patients are usually first identified due to
the presence of visceral symptoms, including prolonged
unexplained neonatal jaundice, splenomegaly or hep-
atomegaly in neonates, or developmental delay in
patients aged >6 months [1, 7]. Each of these character-
istic symptoms is well-represented within this patient
cohort. The new early-onset NP-C SI only includes
symptoms that were able to discriminate between pa-
tients with NP-C and those without NP-C, based on
statistical analysis, irrespective of the symptom’s overall
prevalence within this patient cohort. This resulted in
several of the more typical symptoms, including those
related to developmental delay, being excluded from
the new NP-C SI. Because of this, the new early-onset
NP-C SI will be particularly useful in facilitating screen-
ing in young patients presenting with these clinical
signs and symptoms, and as an educational tool to as-
sist physicians to identify young patients with NP-C.
This retrospective analysis revealed some unexpected
findings in the clinical picture of NP-C. Pulmonary in-
filtrates, which are more often associated with a diag-
nosis of NP-C2 (due to mutations in the NPC2 gene) or
with aspiration pneumonia in late-stage progressive dis-
ease, were unexpectedly common amongst all NP-C
cases (13 %). It is likely that the high incidence of pul-
monary infiltrates is related to the number of patients
with late-stage disease, or with severe forms of early-
onset disease [8]. The frequency of gelastic cataplexy
was also higher than expected amongst NP-C cases,
and presented almost exclusively in older patients
within this cohort (mean age of patients with gelastic
cataplexy, 35 months).
The strongest and most specific predictor of NP-C
in this cohort is family history of the disease, specific-
ally in parents or siblings, which alone is sufficient for
high suspicion of NP-C in patients with unclear med-
ical conditions. A history of NP-C in cousins and
consanguinity of parents were not strongly related to
NP-C cases in this population (Additional file 3: Table
S2). The most common signs and symptoms in pa-
tients aged ≤4 years were visceral symptoms, consist-
ent with classical descriptions of the disease [1]. These
symptoms distinguished well between NP-C cases and
controls, but less well between NP-C cases and NP-C
non-cases. This may reflect the signs and symptoms
that initially lead to NP-C suspicion and referral for
ab
Fig. 3 Receiver operator characteristic (ROC) curve analysis. ROC AUC analysis for both the early-onset and original NP-C SI (a) and for symptom
categories for the early-onset NP-C SI (b). AUC, area under the curve; SI, suspicion index
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agreement with the known progression of the disease,
and in keeping with the young mean age of the patient
population, CNS symptoms were not as common as
visceral signs and symptoms. Despite this, gelastic
cataplexy and VSGP, both identified as specific for
NP-C during the development of the original NP-C SI,
[15] were still found to be highly suggestive of NP-C
in this patient cohort.
Ataxia was not highly specific for NP-C in this popu-
lation, occurring at a similar frequency in NP-C cases
as both NP-C non-cases and controls. Ataxia was rea-
sonably common in early-onset NP-C cases (32 %), but
was not observed as frequently as in the original NP-C
SI cohort (66 % of NP-C cases) [15]. This is likely due
to the majority of the patients in this cohort either be-
ing too young or being too early in disease progression
for CNS signs and symptoms to become apparent [4].
The original NP-C SI tool performed poorly in pa-
tients aged <4 years, [6] but the new early-onset NP-C
SI has much greater discriminatory power. The cut-off
values within the early-onset NP-C SI denoting the
boundaries between low (<3 points), moderate (3–5
points) and high likelihood (≥6 points), were deter-
mined according to the calculated sensitivity andspecificity for each RPS. Despite the relatively low spe-
cificity for detection at these cut-off scores, the sensi-
tivity suggests that a high proportion of patients with
NP-C will be correctly identified. When the original
NP-C SI was applied to the present cohort of early-
onset patients, the ROC AUC (0.603) was comparable
with the subpopulation of patients aged <4 years used
in development of the original NP-C SI (AUC = 0.562)
[6]. This finding suggests that the population charac-
teristics are similar.Conclusion
The newly developed early-onset NP-C SI outper-
forms the original NP-C SI in identifying patients
with NP-C aged ≤4 years. A finding of high likelihood
of NP-C should immediately warrant further con-
firmatory genetic and laboratory testing (e.g. filipin
staining), in accordance with the most recent diagnos-
tic guidelines [7]. Clinical use of this novel tool,
particularly by physicians with limited knowledge of
NP-C, is anticipated to lead to improved detection
rates for NP-C, and detection at an earlier age, sup-
porting monitoring of disease progression and natural
history, and initiation of therapy at the earliest onset
Pineda et al. BMC Pediatrics  (2016) 16:107 Page 9 of 10of neurological and/or visceral symptoms. The ability
of the early-onset NP-C SI tool to correctly identify
NP-C in suspected patients will further validate the
tool, and provide supporting evidence for its use in
clinical practice.
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